Statins reduce deaths from infection and respiratory illness, data eight years on from trial suggest
Results 1 to 1 of 1
  1. #1
    SAM
    benny's Avatar
    Member InfoShowcaseActivity StatusThanks / Tagging Info
    join date|Join Date
    Sep 2006
    post count|Posts
    2,501
    reputation|Rep Power
    130

    Statins reduce deaths from infection and respiratory illness, data eight years on from trial suggest

    ScienceDaily (Aug. 28, 2011) — The death rate among patients prescribed a statin in a major trial that ended in 2003 is still lower than those given a placebo, even though most participants in both groups have been taking statins ever since. ASCOT, the Anglo-Scandinavian Cardiac Outcomes Trial, was stopped early because the statin was so effective at preventing heart attacks and strokes, but a new analysis has shown that eight years on, the most significant difference between the groups is a reduction in deaths from infection and respiratory illness.

    The latest findings, from researchers at Imperial College London, were presented at the European Society of Cardiology Congress in Paris August 28 and simultaneously published in the European Heart Journal.

    In the lipid-lowering arm of the trial, over 10,000 patients in the UK, Ireland and Scandinavia with high blood pressure were randomly allocated either atorvastatin or placebo between 1998 and 2000. In 2003, the trial was stopped early because the statin proved to be highly beneficial in preventing heart attacks and strokes. Since then, most participants from both groups have been taking statins.

    The new analysis looked at the number and cause of deaths among the 4,605 participants in the ASCOT trial who are based in the UK. After 11 years' follow-up, overall mortality is 14 per cent lower in the group originally assigned atorvastatin, due largely to fewer deaths from infection and respiratory illness.

    "This result is very unexpected," said Professor Peter Sever, from the International Centre for Circulatory Health at Imperial College London, who led the study. "The benefits of statins for preventing heart attacks and strokes are well-established, but after long-term follow-up the most significant effects seem to be on deaths from other causes. It's quite remarkable that there is still this difference between the two groups, eight years after the trial finished.

    "Some studies have suggested that statins protect people against death from infectious diseases such as pneumonia. More research is needed to explain how these drugs might have unforeseen actions that prevent deaths from other illnesses."

    Amongst UK participants, in the 11 years since the trial began, 460 of the original statin group have died, compared with 520 of the placebo group. The difference is largely explained by a 36 per cent reduction in deaths from infection and respiratory illness. Deaths from cardiovascular disease were also lower in the original statin group, but the difference was not statistically significant. There was no difference in deaths from cancer.

    The initial results of the ASCOT lipid arm had a major influence on subsequent guidelines recommending the use of statins for people at risk of heart disease, including those produced by NICE in the UK. Another arm of the trial comparing different combinations of blood pressure-lowering drugs also had an important impact on clinical practice.

    The study was investigator-led with funding provided by Pfizer. Professor Sever is a National Institute for Health Research (NIHR) Senior Investigator and he was supported by the Comprehensive Biomedical Research Centre award to Imperial College Healthcare NHS Trust, from the NIHR.

    Story Source:

    The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Imperial College London, via EurekAlert!, a service of AAAS.
    Journal Reference:


    1. P.S. Sever et al. The Anglo-Scandinavian Cardiac Outcomes Trial: 11 year mortality follow-up of the lipid-lowering arm in the UK. European Heart Journal, 2011 DOI: 10.1093/eurheartj/ehr333

    Note: If no author is given, the source is cited instead.


    Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.





    Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement | WordPress Tutorials

  2. # 1a
    India
    Statins reduce deaths from infection and respiratory illness, data eight years on from trial suggest

    Join Date
    Jan 2009
    Posts
    192
     

Thread Information

Users Browsing this Thread

There are currently 1 users browsing this thread. (0 members and 1 guests)

Similar Threads

  1. Replies: 0
    Last Post: 11th August 2011, 02:31
  2. Replies: 0
    Last Post: 4th August 2011, 22:14
  3. Cuba hospital deaths trial begins
    By xman in forum UK news
    Replies: 0
    Last Post: 17th January 2011, 21:12
  4. Replies: 0
    Last Post: 25th November 2010, 11:37
  5. 'New trial' over Corfu gas deaths
    By xman in forum UK news
    Replies: 0
    Last Post: 15th May 2010, 12:24

User Tag List

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •